<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

SLV 319 - Ibipinabant | SLV 319, (S)-(-)-

產(chǎn)品貨號

Axon 1713 CAS [464213-10-3] MF C23H20Cl2N4O2SMW 487.40 Purity: 100% Optical purity: >98% ee Soluble in DMSO Description Potent and highly selective CB1 antagonist (Ki= 7.8 and 7943 nM for CB1 and peripheral cannabinoid CB2, respectively); more potent (100-fold) S-(-)-enantiomer in comparison with opposite R(+)-SLV319 (Axon 1714) References Certificates Categories Extra info JH Lange etal. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J. Med.l?Chem. 2004,?47(3), 627–643. ? JH Lange and CG Kruse. Recent advances in CB1 cannabinoid receptor antagonists. Curr. Opin. Drug Discov. Devel. 2004, 7(4), 498-506.? ? AB Need et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacol. 2006, 184(1), 26–35. Certificate of Analysis Material Safety Data Sheet Cardiovascular CNS Diabetes & Metabolism Pain & Inflammation CB1 A13 CB1 antagonist Chemical name (S)-(-)-3-(4-chlorophenyl)-N'-(4-chlorophenylsulfonyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide Parent CAS No. [464213-10-3] Order Size Unit Price Stock 2 mg €105.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

SLV 319 - Ibipinabant | SLV 319, (S)-(-)-

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1713

CAS [464213-10-3]

MF C23H20Cl2N4O2S
MW 487.40

Purity: 100%
Optical purity: >98% ee
Soluble in DMSO

SLV 319

Description

Potent and highly selective CB1 antagonist (Ki= 7.8 and 7943 nM for CB1 and peripheral cannabinoid CB2, respectively); more potent (100-fold) S-(-)-enantiomer in comparison with opposite R(+)-SLV319 (Axon 1714)

JH Lange etal. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J. Med.l?Chem. 2004,?47(3), 627–643.

JH Lange and CG Kruse. Recent advances in CB1 cannabinoid receptor antagonists. Curr. Opin. Drug Discov. Devel. 2004, 7(4), 498-506.?

AB Need et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacol. 2006, 184(1), 26–35.

Certificate of Analysis
Material Safety Data Sheet

Cardiovascular CNS Diabetes & Metabolism Pain & Inflammation CB1 A13

CB1 antagonist

Chemical name

(S)-(-)-3-(4-chlorophenyl)-N'-(4-chlorophenylsulfonyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide

Parent CAS No.

[464213-10-3]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>